G1 Therapeutics, Inc. (GTHX) Covered Calls

You can sell covered calls on G1 Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GTHX (prices last updated Fri 4:16 PM ET):

G1 Therapeutics, Inc. (GTHX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
3.99 +0.13 3.88 4.00 441K - 0.2
Covered Calls For G1 Therapeutics, Inc. (GTHX)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 17 4 0.35 3.65 9.6% 159%
Jun 21 4 0.65 3.35 19.4% 124%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.